157 related articles for article (PubMed ID: 37606763)
1. Clinical characteristics and prognostic outcomes for adenocarcinoma of esophagogastric junction in early-onset patients: a population-based appraisal.
Lai H; Zheng J; Zhou G; Li Y
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14941-14952. PubMed ID: 37606763
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
3. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.
Hasegawa S; Yoshikawa T
Gastric Cancer; 2010 Jun; 13(2):63-73. PubMed ID: 20602191
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the clinicopathological features and prognostic factors in 734 cases of Chinese Hui and Han patients with adenocarcinoma of the esophagogastric junction.
Cao J; Yang T; Wang G; Zhang H; You Y; Chen J; Yang J; Yang W
Surg Oncol; 2018 Sep; 27(3):556-562. PubMed ID: 30217319
[TBL] [Abstract][Full Text] [Related]
5. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
6. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study.
Chen L; Tang K; Wang S; Chen D; Ding K
Cancer Control; 2021; 28():10732748211026668. PubMed ID: 34155922
[TBL] [Abstract][Full Text] [Related]
8. Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study.
Chen K; Deng X; Yang Z; Yu D; Zhang X; Li W; Xie D; He Z; Cheng D
Expert Rev Gastroenterol Hepatol; 2020 Jun; 14(6):491-497. PubMed ID: 32324423
[TBL] [Abstract][Full Text] [Related]
9. Effect of Marital Status on the Survival of Patients With Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Study.
Wang S; Chen L; Chen D; Chao J; Shao Y; Tang K; Chen W
Cancer Control; 2021; 28():10732748211066309. PubMed ID: 34910613
[TBL] [Abstract][Full Text] [Related]
10. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center.
Hasegawa S; Yoshikawa T; Cho H; Tsuburaya A; Kobayashi O
World J Surg; 2009 Jan; 33(1):95-103. PubMed ID: 18958523
[TBL] [Abstract][Full Text] [Related]
11. Influence of Primary Tumor Resection on Survival of Patients With Metastatic Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Analysis.
Chen J; Jia X; Chen H; Cai J; Chen L
Cancer Control; 2023; 30():10732748231208313. PubMed ID: 37851478
[TBL] [Abstract][Full Text] [Related]
12. Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction.
Reynolds JV; Ravi N; Muldoon C; Larkin JO; Rowley S; O'Byrne K; Hollywood D; O'Toole D
World J Surg; 2010 Dec; 34(12):2821-9. PubMed ID: 20827475
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study.
Xu H; Zhang L; Miao J; Liu S; Liu H; Jia T; Zhang Q
World J Surg Oncol; 2020 Jun; 18(1):144. PubMed ID: 32593312
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and Clinicopathological Significance of Lymph Node Metastasis in the Esophagogastric Junction Adenocarcinoma.
Urakawa N; Kanaji S; Suzuki S; Sawada R; Harada H; Goto H; Hasegawa H; Yamashita K; Matsuda T; Oshikiri T; Kakeji Y
Anticancer Res; 2022 Feb; 42(2):1051-1057. PubMed ID: 35093906
[TBL] [Abstract][Full Text] [Related]
15. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction.
Mine S; Watanabe M; Kumagai K; Okamura A; Yuda M; Hayami M; Yamashita K; Imamura Y; Ishizuka N
Dis Esophagus; 2019 Dec; 32(11):. PubMed ID: 30791046
[TBL] [Abstract][Full Text] [Related]
17. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
18. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
[TBL] [Abstract][Full Text] [Related]
19. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
Blank S; Rachakonda S; Keller G; Weichert W; Lordick F; Langer R; Springfeld C; Bruckner T; Becker K; Kumar R; Ott K
BMC Cancer; 2014 Feb; 14():58. PubMed ID: 24490800
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of lower perigastric lymph nodes dissection in Siewert type II/III adenocarcinoma of esophagogastric junction: a retrospective propensity score matched study.
Li ZL; Zhao LY; Zhang WH; Liu K; Pang HY; Chen XL; Chen XZ; Yang K; Hu JK
Langenbecks Arch Surg; 2022 May; 407(3):985-998. PubMed ID: 34792614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
